Keywords: tirofiban, cuts, mortality, unstable, angina, patients, merck

Tirofiban Cuts Mortality In Unstable Angina Patients

Article | 26 March 1997

Print This

Merck & Co's glycoprotein IIb/IIIa inhibitor Aggrastat (tirofiban) cutthe risk of death, heart attack and refractory ischemia by over a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in